Results of a Phase 2 clinical trial show that elotuzumab in combination with Revlimid and low-dose dexamethasone is safe and effective in relapsed/refractory multiple myeloma patients.

“Elotuzumab in combination with Revlimid and low-dose dexamethasone has a very high response rate,” said Dr. Philippe Moreau from the University Hospital in Nantes, France, when he presented the findings at the 47^th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

“[The combination] seems to be superior to Revlimid plus high-dose dexamethasone,” he added.

In a summary talk about potential…

Results of a recent German study show that the chromosomal abnormalities del(17p13) and +1q21 may reduce overall survival in relapsed/refractory multiple myeloma patients receiving Revlimid-dexamethasone compared to patients without these abnormalities.

The results also indicate that patients with t(14;16) receiving Revlimid-dexamethasone have a shorter time to disease progression than patients without this abnormality. In addition, patients with del(13q14) in combination with certain other chromosomal abnormalities may have decreased response rates and a shorter time to disease progression.

The study authors, however, recommended additional evaluation of these chromosomal abnormalities in larger…

Results of a recent Italian study show that a four-drug combination regimen of Velcade, Doxil, dexamethasone, and thalidomide may be more effective than two- or three-drug combinations for multiple myeloma patients who have relapsed or are resistant to prior treatment.

“This study clearly reinforced the idea that aggressive therapy, even in the second-line relapse setting, is of great value,” said Dr. Mario Curti, a hematologist at Los Alamitos Medical Center in Los Alamitos, California, who was not involved in the study. “It allows another treatment option to be considered in…

Results of a recently published study show that a steroid-free regimen of Velcade and thalidomide is effective in newly diagnosed multiple myeloma patients.

This finding is particularly significant for patients who are unable to tolerate treatment with steroids due to their side effects, according to the study’s lead author Dr. Ivan Borello from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore,

“The purpose of this study was to develop a therapy that could be used for patients in whom steroids for one reason or another were contraindicated.  Those…

The results of a recent Japanese study suggest that a vincristine-doxorubicin-dexamethasone regimen without intermittent high-dose dexamethasone reduces the risk of bacterial infection in multiple myeloma patients without affecting the treatment’s efficacy. 

Based on these findings, the study authors recommended avoiding the administration of intermittent high-dose dexamethasone with the vincristine-doxorubicin-dexamethasone regimen in myeloma patients at high risk for infection. 

The combination treatment of vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (Decadron) plus high-dose pulses of dexamethasone (referred to as VAD-HD) was first approved as a treatment for advanced multiple…